Wells Fargo Maintains Overweight on BridgeBio Pharma, Raises Price Target to $102

Wells Fargo analyst Derek Archila maintains BridgeBio Pharma (NASDAQ:BBIO) with a Overweight and raises the price target from $98 to $102.